23 enrolling by invitation. 23 Phase 2, 7 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Enrolling by invitation 23 |
| Phase 1 | 7 | Enrolling by invitation 7 |
| Phase 3 | 4 | Enrolling by invitation 4 |
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 73 | 2026-09-01 | 2026-09-10 |
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Enrolling by invitation | Bnai Zion Medical Center | 12 | 2026-06-01 | 2026-07-08 |
| Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 55 | 2026-04-13 | 2026-10-05 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). HVA - Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 40 | 2026-04-01 | 2026-04-08 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| RVU120 Rollover Study RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) | Phase 2 | Enrolling by invitation | Ryvu Therapeutics SA | 14 | 2025-12-04 | 2026-09-17 |
| Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2025-09-10 | 2026-09-08 |
| Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum - Probiotics, Gastrointestinal Diseases | Phase 2 | Enrolling by invitation | National Institute of Pediatrics, Mexico | 120 | 2025-02-01 | 2025-03-14 |
| A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) PM359 - Chronic Granulomatous Disease, Granulomatous Disease, Chronic | Phase 1 / Phase 2 | Enrolling by invitation | Prime Medicine, Inc. | 12 | 2024-10-17 | 2026-04-06 |
| pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47 - p47, Autosomal Recessive | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2024-06-25 | 2026-11-18 |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone - Plasma Cell Myeloma | Phase 2 | Enrolling by invitation | Sanofi | 70 | 2023-04-05 | 2026-10-15 |
| Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA 3D hypoxia-preconditioned UC-MSC group, 2D UC-MSC group - Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory | Phase 1 / Phase 2 | Enrolling by invitation | Chinese PLA General Hospital | 40 | 2022-08-01 | 2026-06-23 |
| Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions - Acute Myeloid Leukemia | Phase 2 | Enrolling by invitation | Michael Pulsipher | 30 | 2021-08-24 | 2025-05-04 |
| The BENeFiTS Trial in Beta Thalassemia Intermedia Benserazide Only Product - Beta Thalassemia Intermedia, Sickle Cell Disease | Phase 1 / Phase 2 | Enrolling by invitation | Phoenicia BioScience | 36 | 2020-10-05 | 2025-08-15 |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) ASTX727 - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Enrolling by invitation | Taiho Oncology, Inc. | 332 | 2019-09-30 | 2026-07-28 |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Enrolling by invitation | Landspitali University Hospital | 80 | 2019-06-24 | 2019-08-16 |
Showing 20 of 23. Sign in to see all of them.
Leukemia, Myeloid, Acute (8) · Granulomatous Disease, Chronic (4) · Multiple Myeloma (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Neoplasm, Residual (2) · Agammaglobulinemia (1) · Anemia, Aplastic (1) · Anemia, Sickle Cell (1) · Common Variable Immunodeficiency (1) · Gastrointestinal Diseases (1) · Granulomatous Disease, Chronic, Autosomal Recessive, Cytochrome B-Positive, Type I (1) · Immunologic Deficiency Syndromes (1) · Job Syndrome (1) · Leukemia, Biphenotypic, Acute (1)
Hemic and Lymphatic Diseases (23) · Neoplasms (16) · Neoplasms by Histologic Type (16) · Immune System Diseases (13) · Leukemia (13) · Leukemia, Myeloid (9) · Lymphoproliferative Disorders (9) · Immunoproliferative Disorders (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Lymphatic Diseases (7) · Disease Attributes (6) · Chronic Disease (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)
Azacitidine (2) · Busulfan (2) · Dexamethasone (2) · Induction Chemotherapy (2) · Lenalidomide (2) · Opiate Substitution Treatment (2) · carfilzomib (2) · Cytarabine (1) · Fibroblast Growth Factor 7 (1) · Filgrastim (1) · Genes (1) · Homoharringtonine (1) · Lisaftoclax (1) · Maintenance (1) · Sirolimus (1)
Guangdong Second Provincial General Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · First Affiliated Hospital of Zhejiang University (2) · Michael Pulsipher (2) · Autolus Limited (1) · Bnai Zion Medical Center (1) · Chinese PLA General Hospital (1) · Landspitali University Hospital (1) · National Institute of Pediatrics, Mexico (1) · Paul Szabolcs (1) · Phoenicia BioScience (1) · Prime Medicine, Inc. (1) · Ryvu Therapeutics SA (1) · SWOG Cancer Research Network (1) · Sanofi (1)
United States (12) · China (8) · Canada (3) · France (3) · Spain (3) · Italy (2) · Poland (2) · United Kingdom (2) · Armenia (1) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Czechia (1)
Elizabeth M Kang, M.D. (2) · Anjali S Advani (1) · Guopan Yu, PhD (1) · Hanny D Al-Samkari, MD (1) · Kevin Kuo, MD (1) · Michael L Pulsipher, MD (1) · Michael Pulsipher, MD (1) · Paul Szabolcs, MD (1) · Sara Espinosa-Padilla, Ph.D. (1) · Sigurdur Y Kristinsson, MD, PhD (1) · Sujit Sheth, MD MS (1) · Suk S De Ravin, M.D. (1) · Susan Perrine, MD (1) · Sylvia Singer, MD (1)
PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 25040088, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 35776909, PMID 39042892, PMID 41358590, PMID 9718381
2018 (1), 2023 (1), 2025 (1), R33HL147845 (1)